Trial Watch: Phase II and Phase III attrition rates 2011–2012

@article{Arrowsmith2013TrialWP,
  title={Trial Watch: Phase II and Phase III attrition rates 2011–2012},
  author={John Arrowsmith and P. Miller},
  journal={Nature Reviews Drug Discovery},
  year={2013},
  volume={12},
  pages={569-569}
}
  • John Arrowsmith, P. Miller
  • Published 2013
  • Medicine
  • Nature Reviews Drug Discovery
  • Figures and Topics from this paper.

    Explore Further: Topics Discussed in This Paper

    Flexible Drug Approval Policies
    CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
    18
    Novel methods for early phase clinical trials
    Drug Metabolism in Early Stage Drug Discovery and Drug Development
    Improved predictive models for pre-clinical drug toxicity studies
    A Bayesian paradigm for decision-making in proof-of-concept trials
    4